Lana Pine

The limited impact of past policy interventions to increase biosimilars uptake in Belgium suggests a need for individualized, proactive measures.

Results showed even at a 55% discount, the biosimilar adalimumab-atto still costs more than double the launch price of reference adalimumab.

Women with psoriatic arthritis reported higher mean pain and worse mean patient global assessment when compared with men.

The main pharmacokinetic parameters were comparable between the tocilizumab reference and the biosimilar cohorts.

No statistically significant differences in retention rates were observed among those treated with baricitinib monotherapy or in combination with methotrexate.

At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.

Juliana Reed, MS, predicts what the future holds regarding biosimilar access in the United States.

Juliana Reed, MS, explains the factors decision-makers need to consider to ensure lower-cost adalimumab biosimilars reach millions of patients in the United States.

Although the recent launch of 7 adalimumab biosimilars should lead to cost savings and better access to medication, the role of pharmacy benefit managers raises concerns for Reed and her team.

Adam Dore, DO, discusses the recent developments in treating psoriatic arthritis and his predictions for the advancement of care in the upcoming year.

The pooled analysis showed the risk of all-cause dementia was decreased in patients with gout, particularly in patients receiving medication.

The use of infliximab, adalimumab and etanercept following biosimilar entry increased by 88.9%, 22.4%, and 14.6%, respectively.

Although the benefits of telehealth are clear, it is not without its challenges. As the field of rheumatology moves into a post-pandemic world, the future of telemedicine hangs in the balance.

An increased hazard ratio was observed for all-cause mortality, including a standardized mortality ratio for accidents and an increased risk for mortality from infections and suicide.

Carola Vinuesa, MD, PhD, recipient of the Lupus Research Alliance Lupus Insight Prize, discovered a mutation in a specific human gene that causes systemic lupus erythematosus.

Patients identified areas of confusion in data presentation and suggested educational support to better engage with the information provided.

Improvements in CDAI by >5 points were associated with improvements in the 5 PROMIS domains and increased satisfaction with rheumatoid arthritis treatment.

The biosimilar month in review highlights ranibizumab biosimilars for the treatment of nAMD, Optum Rx’s decision to recognize subcutaneous adalimumab-adbm as a preferred brand, and the cost-saving benefits of biosimilars for patients.

The rheumatology month in review features studies reporting increased depression rates among patients with autoimmune disease, interventions designed to decrease chronic pain symptoms in fibromyalgia, and highlights from EULAR 2023.

At month 12, response rate was significantly higher in patients receiving pegloticase and methotrexate when compared with concomitant placebo.

The citrate-free high-concentration formulation and citrate-containing low-concentration of biosimilar adalimumab-bwwd are now available to patients living in the US.

Of the randomized controlled trials identified, only 41% involved patients with depression.

Obstructive sleep apnea was linked to an increased risk of gout in the female subgroup.

Optum Rx announced it will place the biosimilar adalimumab-adbm (Cyltezo) injection on its commercial formulary as a preferred brand.

Most patients with lupus nephritis reported moderate anxiety and moderate depression which impacted their disease activity and quality of life.

Today's episode of Relatable Rheumatology explores chronic pain in patients with rheumatic disease.

Patients with SLE who reported being more satisfied in their lives were more likely to have higher physical and mental component summary scores.

Women with gout were more likely to exhibit chronic kidney disease, heart failure, dementia, diabetes mellites, and obesity, among others, when compared with men.

Among patients with rheumatoid arthritis, fibromyalgia was present in 31% of patients, compared with 4% of controls.

Serum levels of BD-2 at baseline were shown to be significantly linked with subsequent clinical response in patients with psoriatic arthritis.